Wall Street brokerages expect Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Rating) to report sales of $220.08 million for the current quarter, Zacks reports. Five analysts have made estimates for Sarepta Therapeutics’ earnings, with the highest sales estimate coming in at $222.90 million and the lowest estimate coming in at $215.60 million. Sarepta Therapeutics reported sales of $164.09 million in the same quarter last year, which indicates a positive year over year growth rate of 34.1%. The company is scheduled to announce its next earnings results on Monday, January 1st.
According to Zacks, analysts expect that Sarepta Therapeutics will report full-year sales of $889.47 million for the current fiscal year, with estimates ranging from $832.37 million to $910.49 million. For the next fiscal year, analysts expect that the company will report sales of $1.03 billion, with estimates ranging from $930.46 million to $1.15 billion. Zacks Investment Research’s sales averages are an average based on a survey of analysts that follow Sarepta Therapeutics.
Sarepta Therapeutics (NASDAQ:SRPT – Get Rating) last released its earnings results on Wednesday, May 4th. The biotechnology company reported ($1.20) earnings per share for the quarter, beating the consensus estimate of ($1.34) by $0.14. Sarepta Therapeutics had a negative return on equity of 52.06% and a negative net margin of 46.56%. The business had revenue of $210.83 million for the quarter, compared to the consensus estimate of $208.25 million. During the same quarter last year, the business posted ($2.10) earnings per share. The business’s quarterly revenue was up 43.5% compared to the same quarter last year.
Shares of SRPT opened at $68.84 on Wednesday. Sarepta Therapeutics has a 52-week low of $61.28 and a 52-week high of $101.24. The stock has a market cap of $6.02 billion, a PE ratio of -16.24 and a beta of 1.29. The firm’s fifty day moving average is $76.49 and its two-hundred day moving average is $78.71. The company has a quick ratio of 5.13, a current ratio of 5.56 and a debt-to-equity ratio of 1.28.
Several institutional investors and hedge funds have recently added to or reduced their stakes in SRPT. Arizona State Retirement System increased its stake in Sarepta Therapeutics by 0.7% during the 3rd quarter. Arizona State Retirement System now owns 20,643 shares of the biotechnology company’s stock worth $1,909,000 after buying an additional 134 shares during the period. M&T Bank Corp increased its position in shares of Sarepta Therapeutics by 2.1% in the 4th quarter. M&T Bank Corp now owns 6,966 shares of the biotechnology company’s stock valued at $627,000 after purchasing an additional 140 shares during the last quarter. Sigma Planning Corp lifted its position in shares of Sarepta Therapeutics by 1.6% during the 4th quarter. Sigma Planning Corp now owns 13,780 shares of the biotechnology company’s stock worth $1,241,000 after purchasing an additional 220 shares during the last quarter. Sit Investment Associates Inc. lifted its holdings in Sarepta Therapeutics by 0.5% during the 1st quarter. Sit Investment Associates Inc. now owns 41,415 shares of the biotechnology company’s stock worth $3,235,000 after buying an additional 225 shares during the last quarter. Finally, Advisors Asset Management Inc. raised its position in shares of Sarepta Therapeutics by 1.0% during the 4th quarter. Advisors Asset Management Inc. now owns 23,780 shares of the biotechnology company’s stock worth $2,141,000 after acquiring an additional 229 shares in the last quarter. Institutional investors and hedge funds own 81.43% of the company’s stock.
Sarepta Therapeutics Company Profile (Get Rating)
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping.
- Get a free copy of the StockNews.com research report on Sarepta Therapeutics (SRPT)
- Zoom Video Communications Is Primed To Launch Higher
- Fundamental Strength Makes Williams-Sonoma One for Your Recovery Watchlist
- Institutions Buy The Dip In Petco Health and Wellness Company
- Veeva Systems: Increasing NDR and Other Wins
- Autozone Edges Past Advanced Auto Parts In Q1 2022
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.